+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Islet Amyloid Polypeptide - Pipeline Review, H2 2020

  • ID: 5137271
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 50 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • ADM Therapeutics
  • Eli Lilly and Co
  • Neurimmune Holding AG
  • Nordic Bioscience AS
  • reMYND NV
  • Zealand Pharma AS
  • MORE
Islet Amyloid Polypeptide - Pipeline Review, H2 2020

Summary

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle.

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Gastrointestinal and Musculoskeletal Disorders which include indications Type 2 Diabetes, Obesity, Alzheimer's Disease, Non-Alcoholic Steatohepatitis (NASH), Type 1 Diabetes (Juvenile Diabetes), Non Alcoholic Fatty Liver Disease (NAFLD), Osteoarthritis and Parkinson's Disease.

The latest report Islet Amyloid Polypeptide - Pipeline Review, H2 2020, outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
  • The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ADM Therapeutics
  • Eli Lilly and Co
  • Neurimmune Holding AG
  • Nordic Bioscience AS
  • reMYND NV
  • Zealand Pharma AS
  • MORE
  • Introduction
  • Report Coverage
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Overview
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development
  • ADM Therapeutics
  • Eli Lilly and Co
  • Neurimmune Holding AG
  • Nordic Bioscience AS
  • reMYND NV
  • Zealand Pharma AS
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles
  • AC-253 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ADM-116 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Products
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by ADM Therapeutics, H2 2020
  • Pipeline by Eli Lilly and Co, H2 2020
  • Pipeline by Neurimmune Holding AG, H2 2020
  • Pipeline by Nordic Bioscience AS, H2 2020
  • Pipeline by reMYND NV, H2 2020
  • Pipeline by Zealand Pharma AS, H2 2020
  • Dormant Projects, H2 2020
  • Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • ADM Therapeutics
  • Eli Lilly and Co
  • Neurimmune Holding AG
  • Nordic Bioscience AS
  • reMYND NV
  • Zealand Pharma AS
Note: Product cover images may vary from those shown
Adroll
adroll